Prostatic Neoplasms Clinical Trials in Cleveland, Ohio

4 studies are recruiting for prostatic neoplasms in Cleveland, Ohio right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

    The purpose of this study is to assess the efficacy and safety of opevesostat plus daily corticosteroids compared to alternative abiraterone acetate or enzalutamide in participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) previously treated with one next-generation hormonal agen…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University Hospitals Cleveland Medical Center ( Site 0043), Cleveland, Ohio
    Locations
    330 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06136650 on ClinicalTrials.gov

  2. A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer

    The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of JNJ-78278343 in combination with JNJ-95298177 in Part 1 (Dose confirmation) of the study and to determine how safe and tolerable the RP2CD of JNJ-7827834 and JNJ-95298177 with or without JNJ-87189401 is for…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University Hospitals Cleveland Medical Center, Cleveland, Ohio
    Locations
    6 in total
    Run by
    Janssen Research & Development, LLC

    See if you can join NCT07082920 on ClinicalTrials.gov

  3. A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer

    The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of Pasritamig in combination with JNJ-86974680 in Part 1 (Dose finding) of the study and to determine how safe and tolerable the RP2CD is for treatment of participants with advanced prostate cancer in Part 2 (…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University Hospitals Cleveland Medical Center, Cleveland, Ohio
    Locations
    5 in total
    Run by
    Janssen Research & Development, LLC

    See if you can join NCT07319871 on ClinicalTrials.gov

  4. A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de Novo mHSPC) in US Urology Clinics

    Prostate cancer is the most common non-skin cancer among men in the United States. For some men, the cancer has already spread to other parts of the body at the time of diagnosis; this is called metastatic hormone-sensitive prostate cancer (mHSPC). Treatment for mHSPC has advanced significantly, wi…

    Stage
    Not phased
    Ages
    18 and older
    Site
    Precision Point Specialty LLC PPS Analytics, a Specialty Networks LLC Company, Cleveland, Ohio
    Run by
    Bayer

    See if you can join NCT07406282 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.